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Abstract: Neonatal hypoglycaemia is a common condition that can cause seizures and serious brain 
injury in infants. It is diagnosed by blood glucose (BG) measurements, often taken several hours apart. 
Continuous glucose monitoring (CGM) devices can potentially improve hypoglycaemia detection, while 
reducing the number of BG measurements. Calibration algorithms convert the sensor signal into the 
CGM output. Thus, these algorithms can have a direct impact on measures used to quantify excursions 
from normal glycaemic levels. The aim of this study was to quantify the effects of calibration sensor 
error and non-linear filtering of CGM data on measures of hypoglycaemia (defined as BG < 2.6mmol/L) 
in neonates. CGM data was recalibrated using an algorithm that explicitly recognised the high accuracy 
of BG measurements available in this study. Median filtering was also implemented either before or after 
recalibration. Results for the entire cohort show an increase in the total number of hypoglycaemic events 
(161 to 193), duration of hypoglycaemia (2.2 to 2.6% of total data), and hypoglycaemic index (4.9 to 
7.1μmol/L) after recalibration. With the addition of filtering, the number of hypoglycaemic events was 
reduced (193 to 131), with little or no change to the other metrics. These results show how reference 
sensor error and thus calibration algorithms play a significant role in quantifying hypoglycaemia. In 
particular, metrics such as counting the number of hypoglycaemic events were particularly sensitive to 
recalibration and filtering effects. While this conclusion might be expected, its potential impact is 
quantified here, in this case for at-risk neonates for whom hypoglycaemia carries potential long-term 
negative outcomes. 
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1. INTRODUCTION 
Neonatal hypoglycaemia is a common condition that can 
cause seizures and permanent brain injury in newborns 
(Stanley and Baker, 1999). There is a wide range of risk 
factors thought to result in hypoglycaemia including 
prematurity, low birth weight (LBW) or high birth weight 
(HBW), and having a mother with diabetes (Stanley and 
Baker, 1999). There remains significant controversy 
regarding the definition of hypoglycaemia, and consequently, 
the effect it can have on the child’s later development 
(Cornblath et al., 2000, Koh et al., 1988). Diagnosis is 
typically by blood glucose (BG) measurements. However, 
BG measurements are often taken several hours apart and 
hypoglycaemic events between BG measurements can go 
undetected (Harris et al., 2010). Continuous Glucose 
Monitoring (CGM) devices provide a continuous estimate of 
BG concentration and have the potential to improve the 
detection and diagnosis of hypoglycaemia. 
CGM devices were first developed in the 1980’s to help 
individuals with type 1 diabetes manage their glucose levels. 
The first CGM device to be approved by the Food and Drug 
Administration (FDA) was the MiniMed Continuous Glucose 
Monitoring System (CGMS), which was approved for 
commercial use in 1999 (Klonoff, 2000). The CGMS consists 
of a small pager-like device that receives information from a 
sensor inserted into the subcutaneous layer, just beneath the 
skin (Mastrototaro et al., 2002). The sensor is coated with a 
glucose oxidase membrane and produces a small electrical 
current, as glucose in the interstitial fluid is oxidised, that is 
proportional to the glucose concentration. The monitor 
provides a value every 5 minutes or 288 measurements per 
day.  
Independent BG calibration measurements, normally using a 
finger-stick glucometer, are required to convert electrical 
current into meaningful CGM output. Point of care testing 
devices developed largely for diabetic patients that use 
hexakinase enzyme reactions to measure the glucose levels in 
capillary blood are reported to have errors typically in the 
range of 2-10% (Solnica et al., 2003, Roche, 2007, Roche, 
2008, Abbott, 2010). After initial calibration, it is usually 
recommended that CGM devices be calibrated at least 4 times 
daily (Minimed, 2003). A 10 minute time delay is 
incorporated into the calibration process for every sample to 
account for the transport of glucose from the blood to the 
interstitial fluid (Rossetti et al., 2010). 
  
     
 
The retrospective calibration algorithm reconciling BG 
measurements with CGMS readings used by the CGMS 
Systems Solutions Software employs linear regression 
(Klonoff, 2000). The use of linear regression with multiple 
calibration BG measurements available could contribute to 
the CGMS reporting high during hypoglycaemia and 
reporting low during hyperglycaemia (Mastrototaro et al., 
2002). However, it may also balance the impact of large 
sensor errors in finger stick glucose meters. Thus, important 
clinical observations such as the occurrence, severity and 
duration of excursions from normal BG levels may be 
directly affected by the specific calibration algorithm used 
and any assumptions on the quality of reference calibration 
values. Importantly, such biases or errors may have little 
impact on overall care or treatment choices (Signal et al., 
2010).  
More recently CGM devices have been used in research 
settings to evaluate aspects of glucose metabolism in at-risk 
newborn infants (Harris et al., 2010). In this case, laboratory 
determinations of BG concentrations using a glucose oxidase 
method were available for the dataset, and therefore can be 
assumed to be a “gold-standard” assessment. Alternative 
calibration and data-processing algorithms can be applied to 
the CGM readings to take advantage of the high accuracy of 
available BG readings and compared to the default 
calibration algorithm. This study explores and quantifies the 
impact of calibration, calibration sensor error, and non-linear 
filtering on the incidence and severity of hypoglycaemia in 
neonates using CGM devices.  
2. SUBJECTS AND METHODS 
2.1  Subjects 
This study uses CGM data from 50 babies at risk of 
hypoglycaemia who were admitted to the Waikato Hospital 
Newborn Intensive Care Unit (NICU). Table 1 presents the 
cohort demographics for the 50 patients. Demographics are 
presented as median [interquartile range] where applicable. 
Table 1: Patient demographics 
Cohort Demographics
Number of CGM traces 50
Sex (M/F) 26/24
Gestational Age (weeks) 34 [33 - 37]
Birthweight (g) 2172 [1880 - 2990]
Primary Risk (# infants):
Diabetes 15
Premature 19
Small or Large for gestational age 14
Other 2  
2.2  Continuous Glucose Monitoring 
All patients had interstitial glucose monitoring using the 
CGMS® System Gold™ (Medtronic, Minimed, Northridge, 
CA, USA). Monitoring began on admission to the NICU and 
finished after 7 days or when the baby was no longer 
considered to be at risk of hypoglycaemia, whichever came 
first. During the monitoring period nurses were asked to 
record all BG concentrations, feeding and medication for the 
management of hypoglycaemia. However, they remained 
blind to the glucose concentrations determined by the device. 
The device was calibrated per the manufacturer’s 
recommendations and all of the data entered into the device 
was checked against clinical records for accuracy. Upon 
completion of monitoring, data were downloaded to a PC 
using CGMS system solutions software version 3.0C, which 
calibrated the CGM readings retrospectively. 
2.3  Calibration Measurements 
All BG calibration measurements were made using a blood 
gas analyser (Radiometer, ABL800Flex, Copenhagen) using 
the glucose oxidase method. This device has a reading range 
of 0.0 to 60.0mmol/L and a coefficient of variation of 2.1% 
(Harris et al., 2010). Due to the location of the blood gas 
analyser, a short time delay (estimated < 15mins maximum) 
was possible between taking the blood sample and 
introducing it into the device. 
2.4  Calibration Algorithms 
The calibration algorithm used by the CGMS is based on 
linear regression (Mastrototaro et al., 2002, Chee et al., 
2001). The algorithm reduces the impact of inherent error in 
the calibration measurements on the overall accuracy of the 
device. The linear regression algorithm is aimed primarily at 
ambulatory individuals with type 1 diabetes who use the 
CGM device to help manage BG levels. This population 
typically uses a finger stick glucometer, which analyses 
capillary BG and typically has up to 10% measurement error 
(Roche, 2007, Roche, 2008, Abbott, 2010, Solnica et al., 
2003). Hence, the use of linear regression implicitly balances 
reference sensor and CGMS errors, and CGM outputs do not 
necessarily exactly correspond to BG measurements.  
Figure 1 shows an example of how linear regression is used 
in the factory calibration. The crosses represent BG 
calibration measurements plotted against the sensor current 
(Valid_ISIG) sample at the same time, together with the fitted 
regression line. Crosses above the regression line will result 
in the CGM reading low at that time point, and crosses below 
the regression line will result in the CGM reading high.  
Since the calibration measurements in this study were 
determined using a gold standard for BG measurement, the 
data were recalibrated using the algorithm in Table 2, which 
was designed to make better use of these more accurate 
calibration measurements by forcing CGM output through 
BG measurements. It should be noted that there are many 
ways that the data could be recalibrated and the algorithm 
used in this study represents just one example based as 
directly as possible upon the current method (Klonoff, 2000, 
Minimed, 2003). 
  
     
 
8 9 10 11 12
3
3.5
4
4.5
5
I
SIG
 (nA)
B
lo
o
d
 G
lu
c
o
s
e
 (
m
m
o
l/
L
)
 
 
BG - I
SIG
 Pairs
Regression line
 
Figure 1: Example of how linear regression is used in the 
factory calibration. Crosses represent calibration 
measurements, paired with the sensor current at the same 
point in time. 
 
Table 2: Recalibration algorithm used with Blood Gas 
calibration measurements 
 
The recalibration algorithm forces the output CGM trace to 
pass through the calibration BG measurements, while 
preserving the raw sensor current (Valid_ISIG) and Offset 
parameter. At each calibration measurement a value of slope 
(Reqd_slope) is calculated using Equation 2, which will force 
the CGM to pass through the BG. Linear interpolation 
between successive values of Reqd_slope gives the new, 
continuous slope function. The new slope function is inserted 
to Equation 1 with the unmodified Valid_ISIG and Offset 
parameters, to give the recalibrated CGM estimate of BG. 
Forcing the CGM trace through the calibration measurements 
recognises explicitly the higher accuracy of the blood gas 
analyser, and thus provides a comparator to assess the impact 
of calibration on outcome CGM traces. 
2.5  Median Filtering 
Median filters are used to remove unwanted and potentially 
un-physiological high-frequency noise from the CGM signal. 
They have proven to be a simple and effective method of 
removing this noise and smoothing CGM traces (Pretty et al., 
2010). A retrospective composite median filter was used in 
this study because it allows faster and slower glucose 
dynamics to be captured more effectively. The filter averages 
a 3 point median and a 5 point median both centred about the 
time point of interest. The filter was implemented both prior 
to recalibration (on the Valid_ISIG) and post calibration on the 
CGM output to test the effect of applying filtering before and 
after calibration calculations. 
2.6  Analysis 
Four analyses of the CGMS data from the 50 babies were 
performed in this study: 1) Original CGM output; 2) re-
calibrated CGM output; 3) re-calibrated CGM output with 
median filtering on post-calibration readings; and finally, 4) 
re-calibrated CGM output with median filtering the pre-
calibration sensor current (Valid_ISIG). Each of the 
recalibrated variations, with and without filtering, is 
compared to the original CGM output to see the effect of 
recalibrating/filtering on clinical measures of hypoglycaemia. 
The metrics used to quantify hypoglycaemia were: 
 Number: Number of independent hypoglycaemic 
events (CGM < 2.6mmol/L) 
 Duration: Percent of CGM record below 
2.6mmol/L 
 Severity: Lowest measurement of hypoglycaemic 
event. 
 Hypoglycaemic index: Similar in concept to the 
Hyperglycaemic index presented in (Vogelzang et 
al., 2004), defined as the area between the 
2.6mmol/L threshold and the CGM trace (for CGM 
trace < 2.6mmol/L) summed over the entire length 
of stay, normalised by the length of data record. 
Note: the units used in this study are μmol/L, not 
mmol/L as in (Vogelzang et al., 2004). 
 
Factory CGM blood glucose estimation: 
        (1) 
Where: 
BGCGM Estimated blood glucose level by the 
CGM (mmol.L
-1
) 
Slope Calibration parameter found using linear 
regression (mmol.L
-1
/nA) 
Valid_ISIG Electrical current detected by the monitor 
from the sensor (nA) 
Offset Calibration parameter that is used if the 
sensitivity ratio is below a threshold  
 
To recalibrate, rearrange (1) to: 
   (2) 
Where: 
BGCal Blood glucose level for calibration – 
Blood Gas analyser (mmol.L
-1
) 
Reqd_slope Slope that forces BGCGM to pass through 
calibration measurements (mmol.L
-1
/nA) 
Linearly interpolate between Reqd_slope(i) and 
Reqd_slope(i+1) to obtain a continuous slope function for 
i = 1:N-1 BGCal measurements. Replace Slope in (1) with 
the slope function from (2) to obtain recalibrated BGCGM. 
  
     
 
3. RESULTS 
An example of the modified slope parameter after 
recalibration compared to original slope parameter is shown 
in Figure 2 for a representative CGM record.  
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Figure 2: Example of the modification to the slope parameter 
when re-calibrating. 
Figure 3 shows the distribution of CGM errors. CGM error is 
defined as the CGM glucose minus the BG measurement, at 
the time of calibration. The top plot shows the error 
distribution for all of the CGM-BG data (1074 pairs). The 
middle plot shows the distribution of errors for the CGM-BG 
data where either the CGM measurement or the BG 
measurement is less than or equal to 3mmol/L (145 pairs). 
The bottom plot shows the distribution of errors for the 
CGM-BG data where either the CGM measurement or the 
BG measurement is greater than 7mmol/L (62 pairs). In all 3 
plots the dashed vertical line represents the median, and the 
solid vertical lines represent the interquartile range (IQR). 
Figure 4 shows a section of CGM trace comparing original 
(black dashed line), recalibrated (solid blue line), 
Recalibrated and filtered (green dotted line), and Filtered 
Valid_ISIG then recalibrated variations (purple dash-dot line). 
In this example, overall trends in calibration parameters and 
CGM output are preserved. However it is clear in Figure 4 
that metrics of hypoglycaemia will vary for each method of 
signal processing.  
Table 3 compares the number, duration and severity of 
hypoglycaemia events, as well as the hypoglycaemic index 
for each variation of the CGM calibration. The results are 
presented for the overall cohort and per-patient to show any 
potential skewed results from individual patients.  
Table 4 shows the number of patients who gained, lost or 
remained (the same) with/without hypoglycaemia after 
recalibration and filtering, where the middle two rows 
indicate patients who changed status.  
-3 -2 -1 0 1 2 3
0
0.1
0.2
Distribution of CGM,BG errors (CGM - BG)
All BG,CGM pairs
-3 -2 -1 0 1 2 3
0
0.1
0.2
BG or CGM < 3mmol/L
-3 -2 -1 0 1 2 3
0
0.1
0.2
BG or CGM >=  7mmol/L
Error (mmol/L)
 
Figure 3: Distribution of errors between CGM and BG 
measurements with median (dashed vertical line) and 
interquartile range (solid vertical lines), for different glucose 
levels. 
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Figure 4: Comparison of a section of CGM trace containing hypoglycaemia for Original CGM, Recalibrated CGM, 
Recalibrated and Filtered CGM, and Filtered ISIG then Recalibrated. 
  
     
 
Table 3: Effect of recalibration and filtering on recorded CGM hypoglycaemia for the entire cohort and per-patient. 
Results are presented as Median [Inter-quartile range] where applicable. 
Overall cohort results Original CGM data Re-calibrated CGM Re-calibrated and filtered CGM Filtered ISIG and Re-calibrated CGM
Number of Hypoglycaemic events 161 193 131 146
Duration (% of CGM record < 2.6mmol/L) 2.2 2.6 2.5 2.6
Hypoglycaemic index (μmol/L) 4.9 7.1 6.9 6.8
Hypoglycaemia events between 2.4-2.6mmol/L 87 87 51 61
Hypoglycaemia events between 2.2-2.4mmol/L 35 40 35 34
Hypoglycaemia events between 2.0-2.2mmol/L 18 38 23 30
Hypoglycaemia events less than 2.0mmol/L 21 28 22 21
Number of patients with no hypoglycamia 25 19 21 19
Per-patient results
Number of Hypoglycaemic events 3 [2 - 7] 3 [1 - 7] 3 [1 - 4] 2 [1 - 4]
Duration (% of data hypoglycaemic) 1.0 [0.6 - 5.9] 2.0 [0.8 - 3.3] 2.0 [0.8 - 3.6] 1.9 [0.7 - 3.3]
Hypoglycaemic index (μmol/L) 2.1 [0.7 - 6.8] 4.3 [1.0 - 10.1] 4.3 [1.0 - 10.7] 3.9 [0.7 - 9.5]  
 
Table 4: Effect of recalibration and filtering on whether a patient gained, lost or stayed with/without hypoglycaemia 
compared to original CGM data. 
Re-calibrating only Re-calibrating and filtering Filtering ISIG then Re-calibrating
Original hypoglycaemia --> Hypoglycaemia (# patients) 24 22 23
Original hypoglycaemia --> No hypoglycaemia (# patients) 1 3 2
Originally no hypoglycaemia --> Hypoglycaemia (# patients) 8 7 8
Originally no hypoglycaemia --> No hypoglycaemia (# patients) 17 18 17  
 
4. DISCUSSION 
The aim of this study was to investigate how calibration 
sensor error and non-linear filtering of CGM data, both 
together and separately, affect the observed number, duration 
and severity of hypoglycaemia (BG < 2.6mmol/L) in at risk 
preterm babies. This knowledge is important for accurately 
relating hypoglycaemia to long term outcomes. CGM data is 
recalibrated to assess the impact of different, more accurate 
reference sensor measurements.  
Table 3 shows all metrics of hypoglycaemia increased after 
recalibration, which can potentially be explained by skew in 
the distribution of BG vs. CGM readings at low BG 
concentrations.  
Figure 3 shows the distribution of errors between the CGM-
BG paired measurements. The data set contains 1074 paired 
BG-CGM measurements of which 51% have a BG 
measurement higher than the CGM and 49% have a BG 
measurement lower than the CGM, and this is overall 
relatively centred, as expected from the regression aspect of 
the calibration algorithm.  
More importantly, the second plot in Figure 3 shows a 
definite positive shift in the median when only considering 
low glycaemic levels. Of the 145 pairs containing either a 
CGM or BG measurement below 3mmol/L, 63% have a BG 
measurement lower than the CGM. These lower 
measurements pull the CGM trace down to the more accurate 
BG analyser value when recalibrating and cause the 
hypoglycaemia metrics to increase. Additionally, the bottom 
plot in Figure 3 shows the opposite is also true for high BG 
concentrations. At least for our dataset, CGM readings have a 
greater tendency to be lower than their BG counterparts when 
the concentrations are above 7mmol/L. 
When comparing recalibrated CGM data to recalibrated and 
filtered CGM data for the overall cohort, the large reduction 
in the number of observed hypoglycaemic events (193 to 
131) with very little change in hypoglycaemic duration (2.6% 
to 2.5%) can be explained by reference to Figure 4. There are 
two different phenomena that reduce the number of events 
from 4 to 1 in this exemplar case. First, at 3.8 days the peak 
in the CGM trace is trimmed by the filter (filter after 
recalibration) stopping it crossing the normoglycaemic 
threshold and thus reducing the number of hypoglycaemic 
events. The opposite is also likely to occur, where a 
hypoglycaemic event observed in the recalibrated CGM trace 
is removed by filtering (in this case a trough is trimmed). The 
second phenomenon is seen at ~3.88 to 3.9 days where high 
frequency fluctuations in CGM measurements are smoothed 
by the filter. Smoothing high frequency fluctuations around 
the threshold is likely to be the major influence on the 
reduced number of hypoglycaemic events observed. The 
difference in the number of hypoglycaemic events observed 
over the 4 variations of CGM data suggests that this metric 
alone (number of events) may not be reliable when 
classifying clinical hypoglycaemia. 
Table 4 shows the number of patients that gained, lost or 
stayed with/without hypoglycaemia when recalibrated and 
filtered, compared to original CGM data. Of the 25 babies 
who had hypoglycaemia in the original data set 22 to 24 had 
hypoglycaemia in the modified data sets, and, 17 to 18 out of 
25 of babies who had no hypoglycaemia in the original data 
set still had no hypoglycaemia. These results suggest that 
over the entire duration of monitoring, the CGM should be 
  
     
 
consistent ~80% of the time about which patients had 
experienced hypoglycaemia at some stage, independent of 
calibration method.  
5.  CONCLUSIONS 
The aim of this study was to investigate how recalibrating 
and filtering CGM data affects the observed number, duration 
and severity of hypoglycaemia in preterm infants. The results 
suggest that conventional hypoglycaemia metrics are heavily 
dependent on both the CGM reference sensor error and the 
calibration algorithm used. All metrics of hypoglycaemia for 
our cohort increased after recalibration, confirming that the 
standard CGM algorithm tended to overestimate BG at lower 
levels by assuming a higher error, less accurate reference 
sensor. If highly accurate calibration measurements are 
available it may be more appropriate to recalibrate the data, 
especially when trying to accurately classify hypoglycaemia 
or other specific extreme events. 
More importantly and generally, reference sensor error and 
thus calibration algorithms play a significant role in 
quantifying hypoglycaemia using CGM data. In particular, 
metrics such as number of hypoglycaemic events are 
particularly sensitive to recalibration effects. While this 
conclusion may be expected, its potential impact is quantified 
here, in this case for at-risk neonates for whom 
hypoglycaemia may carry long-term negative consequences. 
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